Modulates Replication by Recruiting CUL4 to Chromatin
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
DDB1 Targets Chk1 to the Cul4 E3 Ligase Complex in Normal Cycling Cells and in Cells Experiencing Replication Stress
Published OnlineFirst March 10, 2009; DOI: 10.1158/0008-5472.CAN-08-3382 Research Article DDB1 Targets Chk1 to the Cul4 E3 Ligase Complex in Normal Cycling Cells and in Cells Experiencing Replication Stress Van Leung-Pineda,1 Jiwon Huh,1 and Helen Piwnica-Worms1,2,3 Departments of 1Cell Biology and Physiology and 2Internal Medicine and 3Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, Missouri Abstract protein FANCE (8, 10–12). Chk1 carries out its functions both in the The Chk1 protein kinase preserves genome integrity in normal nucleus and at the centrosome (13). Drugs that block Chk1 kinase proliferating cells and in cells experiencing replicative and activity or enhance its proteolysis by interfering with binding to genotoxic stress. Chk1 is currently being targeted in antican- heat shock protein 90 (HSP90) are currently being tested as cer regimens. Here, we identify damaged DNA-binding protein anticancer agents (14–17). 1 (DDB1) as a novel Chk1-interacting protein. DDB1 is part of Chk1 is regulated by reversible phosphorylation and by an E3 ligase complex that includes the cullin proteins Cul4A ubiquitin-mediated proteolysis. Under periods of replicative stress, and Cul4B. We report that Cul4A/DDB1 negatively regulates the ATRIP/ATR module binds to single-stranded DNA and, Chk1 stability in vivo. Chk1 associates with Cul4A/DDB1 together with Rad17 and the 9-1-1 complex, activates Chk1 in a Claspin-dependent manner (18–22). ATR directly phosphorylates during an unperturbed cell division cycle and both Chk1 317 345 phosphorylation and replication stress enhanced these inter- Chk1 on two COOH-terminal residues: Ser (S317) and Ser actions. -
Geminin Prevents DNA Damage in Vagal Neural Crest Cells to Ensure Normal Enteric Neurogenesis Chrysoula Konstantinidou1,3, Stavros Taraviras2* and Vassilis Pachnis1*
Konstantinidou et al. BMC Biology (2016) 14:94 DOI 10.1186/s12915-016-0314-x RESEARCH ARTICLE Open Access Geminin prevents DNA damage in vagal neural crest cells to ensure normal enteric neurogenesis Chrysoula Konstantinidou1,3, Stavros Taraviras2* and Vassilis Pachnis1* Abstract Background: In vertebrate organisms, the neural crest (NC) gives rise to multipotential and highly migratory progenitors which are distributed throughout the embryo and generate, among other structures, the peripheral nervous system, including the intrinsic neuroglial networks of the gut, i.e. the enteric nervous system (ENS). The majority of enteric neurons and glia originate from vagal NC-derived progenitors which invade the foregut mesenchyme and migrate rostro-caudally to colonise the entire length of the gut. Although the migratory behaviour of NC cells has been studied extensively, it remains unclear how their properties and response to microenvironment change as they navigate through complex cellular terrains to reach their target embryonic sites. Results: Using conditional gene inactivation in mice we demonstrate here that the cell cycle-dependent protein Geminin (Gem) is critical for the survival of ENS progenitors in a stage-dependent manner. Gem deletion in early ENS progenitors (prior to foregut invasion) resulted in cell-autonomous activation of DNA damage response and p53-dependent apoptosis, leading to severe intestinal aganglionosis. In contrast, ablation of Gem shortly after ENS progenitors had invaded the embryonic gut did not result in discernible survival or migratory deficits. In contrast to other developmental systems, we obtained no evidence for a role of Gem in commitment or differentiation of ENS lineages. The stage-dependent resistance of ENS progenitors to mutation-induced genotoxic stress was further supported by the enhanced survival of post gut invasion ENS lineages to γ-irradiation relative to their predecessors. -
Homo-Protacs for the Chemical Knockdown of Cereblon
Homo-PROTACs for the Chemical Knockdown of Cereblon Stefanie Lindner 60th ASH Annual Meeting and Exposition December 1, 2018 San Diego , CA IMiDs modulate substrate specificity of the CRBN E3 ligase Thalidomide Lenalidomide omalidomide IKZF1 Multiple IKZF3 Myeloma CRBN Proteasomal CK1α del(5q) MDS Neo- E3 ubiquitin ligase degradation substrate SALL4 Teratogenicity Ito et al., 2010, Science Krönke et al., 2014 Science Lu et al., 2014, Science Krönke et al., 2015, Nature Donovan et al., 2018, Elife Matyskiela et al., 2018, Nat Chem Biol. Proteolysis Targeting Chimeras (PROTACs) Bifunctional molecules for degradation of proteins of interest (POI) Thalidomide POI Lenalidomide ligand Pomalidomide linker POI IMiD CRBN PROTAC Sakamoto et. al, 2001, PNAS Schneekloth et. al, 2004, J Am Chem Soc. Lu et al., 2015, Chem Biol Winter et al., 2017, Mol Cell. Proteolysis Targeting Chimeras (PROTACs) Bifunctional molecules for degradation of proteins of interest (POI) POI IMiD CRBN Proteasomal PROTAC degradation Sakamoto et. al, 2001, PNAS Schneekloth et. al, 2004, J Am Chem Soc. Lu et al., 2015, Chem Biol Winter et al., 2017, Mol Cell. Homodimeric pomalidomide-based PROTACs Linker (size X) O O O HN O O NH O O HN NH O N N O Homo-bifunctional molecules O O Chemical Formula: C36H40N6O11 Molecular Weight: 732,75 Pomalidomide Pomalidomide Chemically CRBN Pom Pom CRBN induced CRBN knockdown Proteasomal POI = CRBN degradation Homodimeric pomalidomide-based PROTACs corresponding linker substructures No. of linear CRBN IKZF1 Linker linker atoms degradation degradation -
The CUL4A Ubiquitin Ligase Is a Potential Therapeutic Target in Skin Cancer and Other Malignancies
Chinese Journal of Cancer Review The CUL4A ubiquitin ligase is a potential therapeutic target in skin cancer and other malignancies Jeffrey Hannah1 and Peng-Bo Zhou1,2 Abstract Cullin 4A (CUL4A) is an E3 ubiquitin ligase that directly affects DNA repair and cell cycle progression by targeting substrates including damage-specific DNA-binding protein 2 (DDB2), xeroderma pigmentosum complementation group C (XPC), chromatin licensing and DNA replication factor 1 (Cdt1), and p21. Recent work from our laboratory has shown that Cul4a-deficient mice have greatly reduced rates of ultraviolet-induced skin carcinomas. On a cellular level, Cul4a-deficient cells have great capacity for DNA repair and demonstrate a slow rate of proliferation due primarily to increased expression of DDB2 and p21, respectively. This suggests that CUL4A promotes tumorigenesis (as well as accumulation of skin damage and subsequent premature aging) by limiting DNA repair activity and expediting S phase entry. In addition, CUL4A has been found to be up-regulated via gene amplification or overexpression in breast cancers, hepatocellular carcinomas, squamous cell carcinomas, adrenocortical carcinomas, childhood medulloblastomas, and malignant pleural mesotheliomas. Because of its oncogenic activity in skin cancer and up-regulation in other malignancies, CUL4A has arisen as a potential candidate for targeted therapeutic approaches. In this review, we outline the established functions of CUL4A and discuss the E3 ligase’s emergence as a potential driver of tumorigenesis. Key words Ubiquitination, cullins, DNA damage, cell cycle regulation, skin cancer, therapeutic targets For most cellular proteins, stability and degradation are scaffold, and one or multiple substrate-recruiting proteins at the regulated by the ubiquitin-proteosome system in which proteins are N-terminus[1,2]. -
Investigation of the Interplay Between SKP2, CDT1 and Geminin in Cancer Cells
1 Investigation of the interplay between SKP2, CDT1 and Geminin in cancer cells 2 3 Andrea Ballabeni¶*, Raffaella Zamponi§ 4 5 ¶Department of Systems Biology, Harvard Medical School, Boston, MA, USA 6 (Current affiliation: Harvard School of Public Health, Boston, MA, USA) s 7 t n i 8 §Department of Experimental Oncology, European Institute of Oncology, Milan, Italy r P 9 (Current affiliation: Novartis Institutes of Biomedical research, Cambridge, MA, USA) e r 10 P 11 *Corresponding author E-mail: [email protected], [email protected] 12 13 Abstract 14 Geminin has a dual role in the regulation of DNA replication: it inhibits replication factor CDT1 15 activity during the G2 phase of the cell cycle and promotes its accumulation at the G2/M 16 transition. In this way Geminin prevents DNA re-replication during G2 phase and ensures that 17 DNA replication is efficiently executed in the next S phase. CDT1 was shown to associate with 18 SKP2, the substrate recognition factor of the SCF ubiquitin ligase complex. We investigated the 19 interplay between these three proteins in cancer cell lines. We show that Geminin, CDT1 and 20 SKP2 could possibly form a complex and propose the putative regions of CDT1 and Geminin 21 involved in the binding. We also show that, despite the physical interaction, SKP2 depletion does 22 not substantially affect CDT1 and Geminin protein levels. Moreover, we show that while 1 PeerJ PrePrints | http://dx.doi.org/10.7287/peerj.preprints.794v1 | CC-BY 4.0 Open Access | rec: 16 Jan 2015, publ: 16 Jan 2015 1 Geminin and CDT1 levels fluctuate, SKP2 levels, differently than in normal cells, are almost 2 steady during the cell cycle of the tested cancer cells. -
Geminin-Deficient Neural Stem Cells Exhibit Normal Cell Division and Normal Neurogenesis
Geminin-Deficient Neural Stem Cells Exhibit Normal Cell Division and Normal Neurogenesis Kathryn M. Schultz1,2, Ghazal Banisadr4., Ruben O. Lastra1,2., Tammy McGuire5, John A. Kessler5, Richard J. Miller4, Thomas J. McGarry1,2,3* 1 Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, 2 Department of Cell and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, 3 Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, 4 Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, 5 Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America Abstract Neural stem cells (NSCs) are the progenitors of neurons and glial cells during both embryonic development and adult life. The unstable regulatory protein Geminin (Gmnn) is thought to maintain neural stem cells in an undifferentiated state while they proliferate. Geminin inhibits neuronal differentiation in cultured cells by antagonizing interactions between the chromatin remodeling protein Brg1 and the neural-specific transcription factors Neurogenin and NeuroD. Geminin is widely expressed in the CNS during throughout embryonic development, and Geminin expression is down-regulated when neuronal precursor cells undergo terminal differentiation. Over-expression of Geminin in gastrula-stage Xenopus embryos can expand the size of the neural plate. The role of Geminin in regulating vertebrate neurogenesis in vivo has not been rigorously examined. To address this question, we created a strain of Nestin-Cre/Gmnnfl/fl mice in which the Geminin gene was specifically deleted from NSCs. -
Geminin Deploys Multiple Mechanisms to Regulate Cdt1 Before Cell Division Thus Ensuring the Proper Execution of DNA Replication
Geminin deploys multiple mechanisms to regulate Cdt1 before cell division thus ensuring the proper execution of DNA replication Andrea Ballabenia, Raffaella Zamponib, Jodene K. Moorea, Kristian Helinc,d, and Marc W. Kirschnera,1 aDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115; bNovartis Institutes for Biomedical Research, Cambridge, MA 02139; cBiotech Research and Innovation Centre and dCentre for Epigenetics, University of Copenhagen, 2200 Copenhagen, Denmark Contributed by Marc W. Kirschner, June 7, 2013 (sent for review March 4, 2013) Cdc10-dependent transcript 1 (Cdt1) is an essential DNA replication the initiation of S phase and its duration. We show that although protein whose accumulation at the end of the cell cycle promotes Cdt1 protein accumulates in G2 phase, it still turns over very the formation of pre-replicative complexes and replication in the quickly and that to produce high Cdt1 levels when cells exit next cell cycle. Geminin is thought to be involved in licensing rep- mitosis into G1, the accumulation in G2 must overcome degra- lication by promoting the accumulation of Cdt1 in mitosis, because dation. This regulation is a product of Geminin’s positive regu- decreasing the Geminin levels prevents Cdt1 accumulation and lation of Cdt1 protein and RNA in the preceding G2 phase. impairs DNA replication. Geminin is known to inhibit Cdt1 func- Degradation of Cdt1 is not a consequence of DNA damage, be- tion; its depletion during G2 leads to DNA rereplication and check- cause Cdt1 levels decrease upon Geminin depletion even in point activation. Here we show that, despite rapid Cdt1 protein presence of inhibitors of DNA synthesis. -
Quaternary Structure of the Human Cdt1-Geminin Complex Regulates DNA Replication Licensing
Quaternary structure of the human Cdt1-Geminin complex regulates DNA replication licensing V. De Marcoa,1, P. J. Gillespieb,2,A.Lib,2,3, N. Karantzelisc, E. Christodouloua,1, R. Klompmakerd, S. van Gerwena, A. Fisha, M. V. Petoukhove, M. S. Iliouf,4, Z. Lygerouf, R. H. Medemad, J. J. Blowb,5, D. I. Svergune, S. Taravirasc, and A. Perrakisa,5 aDepartment of Biochemistry, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands; bWellcome Trust Centre for Gene Regulation and Expression, College of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom; Departments of cPharmacology and fBiology, Medical School, University of Patras, 26500 Rio, Patras, Greece; dDepartment of Medical Oncology and Cancer Genomics Center, Laboratory of Experimental Oncology, University Medical Center Utrecht, Universiteitsweg 100, 3584CG Utrecht, The Netherlands; and eEuropean Molecular Biology Laboratory, Hamburg Outstation, Notkestrasse 85, D-22603 Hamburg, Germany Edited by John Kuriyan, University of California, Berkeley, CA, and approved October 2, 2009 (received for review May 14, 2009) All organisms need to ensure that no DNA segments are rerepli- the remainder becomes inactivated and incapable of inhibiting Cdt1 cated in a single cell cycle. Eukaryotes achieve this through a (16–18). The remaining Geminin gets reactivated in the next cell process called origin licensing, which involves tight spatiotemporal cycle, through a mechanism that is not well understood, but is control of the assembly of prereplicative complexes (pre-RCs) onto dependent on the nuclear import of Geminin, which restores its chromatin. Cdt1 is a key component and crucial regulator of pre-RC ability to block Cdt1 (16, 19, 20). -
The Role of the C-Terminus Merlin in Its Tumor Suppressor Function Vinay Mandati
The role of the C-terminus Merlin in its tumor suppressor function Vinay Mandati To cite this version: Vinay Mandati. The role of the C-terminus Merlin in its tumor suppressor function. Agricultural sciences. Université Paris Sud - Paris XI, 2013. English. NNT : 2013PA112140. tel-01124131 HAL Id: tel-01124131 https://tel.archives-ouvertes.fr/tel-01124131 Submitted on 19 Mar 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. 1 TABLE OF CONTENTS Abbreviations ……………………………………………………………………………...... 8 Resume …………………………………………………………………………………… 10 Abstract …………………………………………………………………………………….. 11 1. Introduction ………………………………………………………………………………12 1.1 Neurofibromatoses ……………………………………………………………………….14 1.2 NF2 disease ………………………………………………………………………………15 1.3 The NF2 gene …………………………………………………………………………….17 1.4 Mutational spectrum of NF2 gene ………………………………………………………..18 1.5 NF2 in other cancers ……………………………………………………………………...20 2. ERM proteins and Merlin ……………………………………………………………….21 2.1 ERMs ……………………………………………………………………………………..21 2.1.1 Band 4.1 Proteins and ERMs …………………………………………………………...21 2.1.2 ERMs structure ………………………………………………………………………....23 2.1.3 Sub-cellular localization and tissue distribution of ERMs ……………………………..25 2.1.4 ERM proteins and their binding partners ……………………………………………….25 2.1.5 Assimilation of ERMs into signaling pathways ………………………………………...26 2.1.5. A. ERMs and Ras signaling …………………………………………………...26 2.1.5. B. ERMs in membrane transport ………………………………………………29 2.1.6 ERM functions in metastasis …………………………………………………………...30 2.1.7 Regulation of ERM proteins activity …………………………………………………...31 2.1.7. -
Delineating the Role of Cooperativity in the Design of Potent Protacs for BTK
Delineating the role of cooperativity in the design of potent PROTACs for BTK Adelajda Zorbaa,b, Chuong Nguyenb, Yingrong Xub, Jeremy Starrb, Kris Borzillerib, James Smithb, Hongyao Zhuc, Kathleen A. Farleyb, WeiDong Dingb, James Schiemerb, Xidong Fengb, Jeanne S. Changb, Daniel P. Uccellob, Jennifer A. Youngb, Carmen N. Garcia-Irrizaryb, Lara Czabaniukb, Brandon Schuffb, Robert Oliverb, Justin Montgomeryb, Matthew M. Haywardb, Jotham Coeb, Jinshan Chenb, Mark Niosid, Suman Luthrae, Jaymin C. Shahe, Ayman El-Kattand, Xiayang Qiub, Graham M. Westb, Mark C. Noeb, Veerabahu Shanmugasundaramb, Adam M. Gilbertb, Matthew F. Brownb, and Matthew F. Calabreseb,1 aInternal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA 02139; bDiscovery Sciences, Pfizer Worldwide Research and Development, Groton, CT 06340; cComputational Sciences, Medicinal Sciences, Pfizer Worldwide Research and Development, Groton, CT 06340; dMedicine Design, Pfizer Worldwide Research and Development, Groton, CT 06340; and ePharmaceutical Sciences Small Molecule, Pfizer Worldwide Research and Development, Cambridge, MA 02139 Edited by Vishva M. Dixit, Genentech, San Francisco, CA, and approved June 20, 2018 (received for review March 1, 2018) Proteolysis targeting chimeras (PROTACs) are heterobifunctional cellular compartments and for targets that have Lys residues small molecules that simultaneously bind to a target protein and accessible for ubiquitination. A second selection criterion en route an E3 ligase, thereby leading to ubiquitination and subsequent to efficacious and selective target degradation could be de novo degradation of the target. They present an exciting opportunity to rational design of PROTACs. In a recent report, Gadd et al. (18) modulate proteins in a manner independent of enzymatic or describe an elegant model of PROTAC-facilitated target–ligase signaling activity. -
Regulation of the Intranuclear Distribution of the Cockayne Syndrome Proteins Received: 26 July 2017 Teruaki Iyama, Mustafa N
www.nature.com/scientificreports OPEN Regulation of the Intranuclear Distribution of the Cockayne Syndrome Proteins Received: 26 July 2017 Teruaki Iyama, Mustafa N. Okur, Tyler Golato, Daniel R. McNeill, Huiming Lu , Accepted: 1 November 2018 Royce Hamilton, Aishwarya Raja, Vilhelm A. Bohr & David M. Wilson III Published: xx xx xxxx Cockayne syndrome (CS) is an inherited disorder that involves photosensitivity, developmental defects, progressive degeneration and characteristics of premature aging. Evidence indicates primarily nuclear roles for the major CS proteins, CSA and CSB, specifcally in DNA repair and RNA transcription. We reveal herein a complex regulation of CSB targeting that involves three major consensus signals: NLS1 (aa467-481), which directs nuclear and nucleolar localization in cooperation with NoLS1 (aa302-341), and NLS2 (aa1038-1055), which seemingly optimizes nuclear enrichment. CSB localization to the nucleolus was also found to be important for full UVC resistance. CSA, which does not contain any obvious targeting sequences, was adversely afected (i.e. presumably destabilized) by any form of truncation. No inter-coordination between the subnuclear localization of CSA and CSB was observed, implying that this aspect does not underlie the clinical features of CS. The E3 ubiquitin ligase binding partner of CSA, DDB1, played an important role in CSA stability (as well as DDB2), and facilitated CSA association with chromatin following UV irradiation; yet did not afect CSB chromatin binding. We also observed that initial recruitment of CSB to DNA interstrand crosslinks is similar in the nucleoplasm and nucleolus, although fnal accumulation is greater in the former. Whereas assembly of CSB at sites of DNA damage in the nucleolus was not afected by RNA polymerase I inhibition, stable retention at these sites of presumed repair was abrogated. -
Missense Mutations in the NF2 Gene Result in the Quantitative Loss of Merlin Protein and Minimally Affect Protein Intrinsic Function
Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function Chunzhang Yang, Ashok R. Asthagiri, Rajiv R. Iyer, Jie Lu, David S. Xu, Alexander Ksendzovsky, Roscoe O. Brady1, Zhengping Zhuang1, and Russell R. Lonser1 Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 Contributed by Roscoe O. Brady, February 9, 2011 (sent for review December 29, 2010) Neurofibromatosis type 2 (NF2) is a multiple neoplasia syndrome Results and is caused by a mutation of the NF2 tumor suppressor gene Quantitative Tumor Suppressor Protein Levels and mRNA Expression. that encodes for the tumor suppressor protein merlin. Biallelic NF2 To assess the levels of merlin expression in NF2 tumors, we gene inactivation results in the development of central nervous quantitatively measured merlin expression in microdissected system tumors, including schwannomas, meningiomas, ependy- tumors from NF2 patients using Western blot analysis (Fig. 1A). momas, and astrocytomas. Although a wide variety of missense Quantitative protein analysis revealed a significant reduction in germline mutations in the coding sequences of the NF2 gene can merlin expression in NF2-associated meningiomas and schwan- cause loss of merlin function, the mechanism of this functional loss nomas (95% reduction in merlin expression; seven tumors) com- is unknown. To gain insight into the mechanisms underlying loss pared with normal adjacent central nervous system tissue. of merlin function in NF2, we investigated mutated merlin homeo- Consistent with Western blot analysis of merlin expression in NF2- stasis and function in NF2-associated tumors and cell lines.